The EU AI in antibody discovery market is undergoing a significant surge, driven primarily by growing investments in biotechnology and a heightened focus on personalized medicine. Experts foresee substantial advancements in medicinal antibody development utilizing artificial intelligence, particularly within fields like oncology and immunotherapeut